StockData

Beam Therapeutics vs Regenxbio

BEAM and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BEAM and RGNX compare

Beam Therapeutics is the larger company, worth 4.7 times as much as Regenxbio ($2.4B against $504M).

Beam Therapeutics grew revenue faster over the last twelve months (159% versus 12.0% for Regenxbio).

Beam Therapeutics keeps more of each dollar of sales as profit, with a net margin of −54.7% compared with −113% at Regenxbio.

Beam Therapeutics scores higher on the StockData Score (7 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBEAMRGNX
Size and price
Market cap$2.4B$504M
Share price$22.83$7.64
Change, 1 year4.4%−34.1%
Change, 5 years−74.6%−77.2%
Beta (5Y)1.991.78
Employees511371
StockData Score
Total score7 (better)4
Valuation score1 (better)0
Growth score22
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/S15.1×2.9× (better)
P/B2.2× (better)7.0×
FCF yield−15.8% (better)−49.5%
Fair value$23.90–
Margin of safety4.5%–
Growth
Revenue growth (TTM)159% (better)12.0%
Revenue growth, 5Y average466% (better)2.0%
Profitability
Operating margin−242%−94.1% (better)
Net margin−54.7% (better)−113%
FCF margin−239%−143% (better)
Return on equity−8.1% (better)−138%
Financial health
Debt / equity0.09–
Interest coverage–−3.9×
Current ratio14.57 (better)2.86
Altman Z-score2.72 (better)−3.83
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions106%64.2%
Held by insiders3.4%7.6%
Insider net buying, 12 months−$19.7M$9.6K (better)
Superinvestors holding1–
Short interest, % of float26.1%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.